BrainsWay Ltd.BWAY

$14.89+0.48 (+3.33%)
NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap
$284M
Micro-cap
+219%
2019 — today
10-Year Price
+178%
2019 — today
52-Week Range
$5.74$17.17
Current $14.89· 80%

BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Valuation in context

P/E ratio
42.5
Historically pricey
Historically pricey — last 10 years
P/B ratio
3.7
Historically pricey
Historically pricey — last 10 years
EV / EBITDA
18.5
Historically cheap
Historically cheap relative to the last 10 years
FCF Yield
4.5%
Historically high
Historically high relative to the last 10 years
Free · No credit card needed

Get alerted when BWAY is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.